Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. ROIV
6. AAPL
7. NVDA
8. ACN
9. ODFL
10. USO

Go back to Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
(NASDAQ: LEGN) Delayed: 20.71 -0.81 (3.76%)
Previous Close $21.52    52 Week High $ 
Open $21.63    52 Week Low $ 
Day High $21.97    P/E N/A 
Day Low $20.67    EPS $ 
Volume 282,668